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Abstract
Background: Although alcohol consumption has long been considered as a risk factor for chronic disease, the
relationship to cardiovascular disease (CVD) is complex and involves at least two dimensions: average volume of
alcohol consumption and patterns of drinking. The objective of this contribution was to estimate the burden of
CVD mortality caused by alcohol consumption.
Methods: Risk assessment modelling with alcohol-attributable CVD mortality as primary outcome. The mortality
burden of ischaemic heart disease (IHD) and ischaemic stroke (IS) attributable to alcohol consumption was
estimated using attributable-fraction methodology. Relative Risk (RR) data for IHD and IS were obtained from the
most comprehensive meta-analyses (except for Russia and surrounding countries where alcohol RR data were
obtained from a large cohort study). Age-group specific RRs were calculated, based on large studies. Data on
mortality were obtained from the World Health Organization’s Global Health Estimates and alcohol consumption
data were obtained from the Global Information System on Alcohol and Health. Risk of former drinkers was
modelled taking into account global differences in the prevalence of sick quitters among former drinkers. Alcohol-
attributable mortality estimates for all other CVD causes except IHD and IS were obtained from the 2014 Global
Status Report on Alcohol and Health.
Results: An estimated 780,381 CVD deaths (441,893 and 338,490 CVD deaths among men and women respectively)
were attributable to alcohol consumption globally in 2012, accounting for 1.4 % of all deaths and 26.6 % of all
alcohol-attributable deaths. This is in contrast to the previously estimated 1,128,273 CVD deaths attributable to
alcohol consumption globally, and represents a decrease of 30.8 % in alcohol-attributable CVD mortality and of
10.6 % in the global burden of all alcohol-attributable deaths.
Conclusions: When the most comprehensive and recent systematic reviews and meta-analyses are taken as bases,
the net impact of alcohol consumption on CVD is lower than previously estimated.
Keywords: Alcohol consumption, Cardiovascular disease, Ischaemic heart disease, Ischaemic stroke, Mortality, Global
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Background
Although alcohol consumption has long been considered
as a risk factor for cardiovascular disease (CVD) [1], the
effect of alcohol consumption on the risk of these dis-
eases is complex [2, 3], as there are beneficial and detri-
mental effects depending on volume and patterns of
alcohol consumption. The consumption of alcohol is
causally related to several major CVD categories: hyperten-
sive diseases [4]; ischaemic heart disease (IHD) [2, 5, 6];
cardiac arrhythmias [7]; ischaemic and haemorrhagic
strokes [8]; and alcoholic cardiomyopathy (which is 100 %
attributable to alcohol) [9]. Alcohol consumption impacts
on CVD via multiple pathways, not the least of which is via
the causal effect on the risk of high blood pressure [4, 10].
This is especially consequential, as high blood pressure is
the most important overall risk factor for the global burden
of disease [11].
The consumption of alcohol has a positive or negative
impact on the risk of CVDs depending on the volume of
alcohol consumed and the way in which alcohol is con-
sumed [2, 3, 10, 12]. Furthermore, the effects of alcohol
on the risk of CVDs can be immediate [3, 13–16] as well
as longer-lasting [3, 17].
Given the complex relationship between alcohol con-
sumption and the risk of CVDs, the quantification of the
health burden of CVDs caused by alcohol consumption
is difficult, especially for IHD and ischaemic stroke (IS),
where the volume of alcohol consumed, the patterns of
alcohol consumption and the beneficial effects of alcohol
have to be taken into consideration. Recent results of
such quantification models can be observed in the com-
parative risk assessments of the Global Burden of
Disease studies [11, 18] and in the monitoring efforts of
the World Health Organization (WHO) in the Global
Status Reports on Alcohol and Health (GSRAH) ([19];
for the underlying alcohol Relative Risk (RR) functions
used in the GSRAH, see [20]).
However, recently published meta-analyses on alcohol
consumption and the risks for CVDs in general and IHD
in particular suggest that new algorithms are required
for modelling the effects of alcohol on ischaemic dis-
eases [21–23]. This article will detail the reasoning be-
hind the use of these new algorithms, and apply the
resulting calculations to data from the recently published
WHO GSRAH which appeared in 2014 and contained
estimates for 2012 [19]. Thus, the main objective of this
article is to estimate the impact of alcohol consumption
on CVD mortality, both globally and regionally, based
on the newest systematic reviews and meta-analyses.
Methods
The burden of IHD and IS attributable to alcohol con-
sumption was modelled using an attributable-fraction
approach, where an attributable fraction is defined as
the burden of disease that would not be present without
the exposure under consideration [24]. In the case of
alcohol consumption as the exposure, this counterfactual
scenario [25] has usually been operationalized by assum-
ing lifetime abstention for the respective population [26].
Exposure and mortality data
The calculation of the Alcohol-Attributable Fraction
(AAF) requires the combination of data on (i) the preva-
lence of different drinking statuses (current drinker,
former drinker, lifetime abstainer), (ii) average consump-
tion among current drinkers, (iii) the prevalence of
people who are heavy episodic drinkers, and (iv) per
capita consumption of alcohol. Exposure estimates for
drinking status by sex, age (age groups: 15 to 34 years of
age, 35 to 64 years of age, and 65 plus years of age; as
usual for comparative risk assessments, no consumption
was assumed for people under 15 years of age) and
country, as well as data on the average drinking level
among drinkers and the prevalence of regular and ir-
regular heavy drinking occasions, were obtained from
the Global Information System on Alcohol and Health
(GISAH) (for a brief description of data sources, see
[27]; http://apps.who.int/gho/data/node.main.GISAH).
As alcohol is a legal substance, there are sales and/or
production, export and import data for every country.
However, as the prevalence of sick quitters (i.e. those
who stopped consuming alcohol because of health rea-
sons) among former drinkers may be different based on
the country (e.g., in Thailand, where lifetime abstention
rates are high, the prevalence of sick quitters among
former drinkers is likely lower than that of European
countries such as Russia), modifications were made to
the prevalence of former drinkers when modelling the
burden of IHD and IS attributable to alcohol consump-
tion (see below). Total per capita consumption of alco-
hol data were obtained from the GISAH (these estimates
were also the basis for exposure estimates used in the
WHO’s 2014 GSRAH [19]).
Data on mortality by sex, age, cause of death and
country for the year 2012 were obtained from the WHO
Global Health Estimates (http://www.who.int/healthinfo/
global_burden_disease/en/).
Risk relations and calculating the alcohol-attributable
fraction (AAF)
In the WHO 2014 GSRAH, the AAFs for most causes of
death were calculated for each cardiovascular cause of
death separately by sex, age (age groups: 15 to 34 years
of age, 35 to 64 years of age, and 65 plus years of age),
and country. To calculate the AAF, the Relative Risks
(RR) for CVD mortality for different groups in compari-
son to lifetime abstainers were multiplied with the
prevalence of these groups. The groups used were
Rehm et al. BMC Public Health  (2016) 16:363 Page 2 of 9
former and current drinkers, where the latter were mod-
elled continuously based on their average drinking per
day level. This modelling strategy has become standard
in comparative risk assessments for alcohol, both for the
Global Burden of Disease Studies [12] and the WHO
GSRAH.
Application of the alcohol-attributable fractions to causes
of death
Alcohol attributable deaths by sex, age, and CVD cause
of death categories were obtained for each country by
multiplying the respective AAFs with the absolute num-
bers of death in the respective categories as defined by
the various categories listed above. For instance, if there
had been 1000 ischemic heart disease deaths for women
ages 35–64 in a country, and if the AAF for this sex, age
and cause of death category was 14 % for this country,
the absolute number of deaths was 140.
Uncertainty
As with all comparative risk analyses for alcohol, un-
certainty was estimated with Monte Carlo methodology,
described in more detail in Additional file 1: Web
Appendix 1.
Differences of the current analyses to the WHO 2014
GSRAH and their scientific basis
We re-conducted the analyses from the WHO’s 2014
GSRAH using data on risk relations (i.e., RR functions)
from new meta-analyses for IHD (for an overview of the
changes, see Table 1), and for IS (where the only changes
were in modelling the “sick quitter effect” [28, 29] and
age-specific alcohol RR functions).
The following information was used to model the relation-
ship between alcohol consumption and both IHD and IS:
1) For both of the included ischaemic disease
categories, namely IHD and IS, there is evidence of a
beneficial effect (quantification for IHD: [5, 12]; for
discussion: [30, 31]; for IS: [8]).
2) For both IHD and IS, there is evidence that with either
irregular or regular heavy drinking occasions, the
beneficial effect disappears [2, 6, 8, 14, 16, 32], which must
be taken into account even for light to medium drinkers.
3) For both IHD and IS, as well as for CVDs in general,
there is evidence that very heavy drinking occasions
(e.g., by people with alcohol dependence) are associated
with detrimental effects [21, 23, 33–35].
4) The effect of former drinking is detrimental
according to meta-analyses [8, 36, 37]; however, most of
these meta-analyses originated in high-income countries,
where drinking over a lifetime is the norm [19], and
where a substantial proportion of people in later
adulthood quit drinking for health reasons [38–40]. As a
consequence, we applied the specific RR for former
drinkers [36] to the total population of former drinkers
only in these regions, and artificially capped the
prevalence of former drinkers for other regions (see
Additional file 1: Web-Appendix 2 for details and
Additional file 1: Web Appendix 3 for the countries
within each region).
The reasoning for capping was mainly because we
wanted to be conservative and restrict the detrimental
impact of former drinking to region, where we actually
have evidence of the phenomenon (but see [41]).
Unless we find better evidence for increased health
risks of former drinkers due to alcohol in low- to mid
income countries, this seems to be the cautious choice.
This decision is also in line with the general rule of the
comparative risk assessments for alcohol to always
choose the more conservative option (e.g., [18]).
5) Additionally, the impact of alcohol on all-cause
mortality and on IHD and IS is age-specific [42].
Accordingly, the alcohol risk for IHD and IS was
modelled based on age-specific RRs estimated based
on the observed effect modification of age on the
relationship between alcohol and IHD and IS [6, 8].
The methodology described above was used for all
countries except for Russia and surrounding countries,
Table 1 Differences in modelling ischaemic heart disease mortality between the 2014 GSRAH and this paper
New algorithms Algorithms from GSRAH
Risk relation curve up to 100 g/day based on [5]; RR ≥ 1 after 60 g/day based on [5]; RR ≥ 1 after 60 g/day
Risk relation curve for 100 g+/day Yes, modelled based on [21, 22] Not included, set to 1
Impact of binge drinking in persons who
drink on average less than 60 g/day
Yes [6] Yes [6]
Modelling the sick quitter effect in
former drinkers
Only for high-income countries where the literature of
alcohol RRs for former drinkers originated (see Additional
file 1: Web appendix 2) [36]
For all countries, ex-drinkers were modelled with
the increased risk of all-cause mortality RRs
Age-specific risk relations For global estimates and for Russia and surrounding countries;
the latter RRs were based on specific Russian data [34, 35].
Details are described in Additional file 1: Web-Appendix 4.
Only for global
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in which case we used country-specific RRs based on a
large epidemiological study from Zaridze and colleagues
[35]. The RRs provided by Zaridze and colleagues have
been recently corroborated by a large cohort study [34],
and are in line with natural experiments such as the
Gorbachev reform [43], where a marked reduction of
alcohol consumption was associated with a marked
reduction of cardiovascular mortality [44]. This shows
that for Russia and surrounding countries, the detrimen-
tal effects of regular and irregular heavy drinking occa-
sions by far outweigh the beneficial effects. Additionally,
for these countries, the risk relations were based on [34]
(see Additional file 1: Web Appendix 4 for details).
The modelling strategy for IHD compared to that used
in the 2014 GSRAH is summarized in Table 1. For IS
mortality, we used the alcohol RRs from the meta-
analyses of Patra and colleagues (for risk curves see [8]);
for people with heavy drinking occasions and an average
volume of alcohol consumption of up to 60 g of pure al-
cohol per day, we set the RR to 1 (for the rationale, see
[14] and above).
This modelling approach is in line with biological
pathways, where regular light to moderate drinking is
associated with more favourable blood lipid profiles,
fibrinogen levels, inhibition of platelet activation, and
anti-inflammatory effects [3, 17, 45]; irregular binge epi-
sodes, which are characteristic of the Russian style of
drinking, lead to opposite effects, and an increase in
hypertension and arrhythmias [3, 46–48]).
The resulting alcohol-attributable burden estimated
using data from the most recent and comprehensive evi-
dence were compared to the results from the last WHO
comparative risk assessment for alcohol consumption
for the year 2012 presented in the 2014 GSRAH [19].
Ethical approval
The study was approved by the Research Ethics Board of
the Centre for Addiction and Mental Health, Toronto,
Canada, as part of the Comparative Risk Analyses for al-
cohol. All the data sources used can be obtained by the
authors upon request.
Results
Relative risk relations between alcohol consumption and
ischaemic diseases
Figures 1 and 2 present the new risk relations for IHD
for men and women, respectively. These graphs take into
account the various RRs by range of underlying expo-
sures found in meta-analyses (see Table 1 for details).
Resulting alcohol-attributable global mortality burden
from ischaemic diseases
Table 2 provides an overview of the recalculated burden
for alcohol-attributable ischaemic diseases by region and
globally. Russia and surrounding countries are presented
as a separate category, as the burdens for these countries
were calculated based on country-specific risks (see [35],
and above). Overall, the new risk relations resulted in a
lower estimated burden, which was driven mainly by a
lower estimated burden for women. Proportionally, the
effect was substantial, and about the same for IHD and
IS; the newly estimated burden for female mortality due
to alcohol-attributable ischaemic diseases is approxi-
mately one-half of what had been previously estimated
(Table 3). The specific contribution of Russia and
surrounding countries to the global burden is apparent:
Fig. 1 Relative risk function for male drinkers for IHD, all ages
combined, using population data from China
Fig. 2 Relative risk function for female drinkers for IHD, all ages
combined, using population data from China
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for men and the risk of IHD, and for women and the
risk of IS, the global alcohol-attributable burden of is-
chaemic diseases would be negative (i.e., exhibiting a
beneficial effect) if results from Russia and surrounding
countries were not included.
Impact on the global alcohol-attributable mortality
burden from CVDs
Table 3 outlines the estimated burden of CVDs attrib-
utable to alcohol using the old and new methodologies.
Using the new methodology, alcohol-attributable CVDs
accounted for 1.4 % of all deaths (1.5 % for men and
1.3 % for women) and for 26.6 % of all alcohol-
attributable deaths (20.1 % for men and 45.7 % for
women). The percentages obtained using the new
methodology differ from the 2014 GSRAH estimates
[19] by−0.6 % with respect to all deaths (−0.2 % for
men and−1.1 % for women) and by−10.6 % with respect
to all alcohol-attributable deaths (−2.6 % for men
and−28.2 % for women).
Table 2 Alcohol-attributable ischaemic mortality by sex and WHO region for 2012a
Disease and region Men Women Total
Deaths 95 % CI Deaths 95 % CI Deaths 95 % CI
Ischaemic heart disease
Africa −3,306 (−9,609 to 2,997) 2,302 (−1,800 to 6,405) −1,004 (−8,525 to 6,517)
Americas −2,433 (−27,910 to 23,043) 3,132 (−12,914 to 19,178) 699 (−29,410 to 30,808)
Eastern-Mediterranean 1,211 (−535 to 2,957) 1,511 (728 to 2,295) 2,722 (808 to 4,636)
Europe without Russia and surrounding countriesb 910 (−35,567 to 37,387) 9,290 (−15,998 to 34,578) 10,200 (−34,185 to 54,586)
Russia and surrounding countriesb 72,656 (21,148 to 124,164) 99,080 (37,263 to 160,896) 171,736 (91,193 to 252,278)
South-East Asia −1,377 (−23,721 to 20,966) 10,710 (4,519 to 16,900) 9,333 (−13,852 to 32,518)
Western-Pacific −13,046 (−67,728 to 41,637) 23,919 (−15,270 to 63,107) 10,873 (−56,402 to 78,148)
Totalc 54,499 (22,551 to 86,446) 150,121 (122,037 to 178,206) 204,620 (162,064 to 247,176)
Ischaemic stroke
Africa 1,037 (−848 to 2,922) −640 (−3,450 to 2,171) 397 (−2,987 to 3,782)
Americas 3,375 (−3,755 to 10,506) −5,626 (−12,292 to 1,040) −2,251 (−12,012 to 7,511)
Eastern-Mediterranean 871 (−581 to 2,323) 132 (−769 to 1,034) 1,003 (−706 to 2,712)
Europe without Russia and surrounding countriesb 8,691 (−5,981 to 23,363) −9,399 (−24,203 to 5,405) −708 (−21,551 to 20,135)
Russia and surrounding countriesb 22,374 (11,573 to 33,174) 46,155 (34,239 to 58,072) 68,529 (52,467 to 84,591)
South-East Asia 7,264 (−1,694 to 5,501) 1,766 (−5,836 to 9,368) 9,030 (−394 to 18,453)
Western-Pacific 20,239 (−2,534 to 43,011) −9,284 (−40,890 to 22,322) 10,954 (−28,001 to 49,910)
Totalc 64,040 (53,211 to 74,868) 23,042 (9,481 to 36,602) 87,082 (69,730 to 104,443)
aFor definitions of WHO regions, see Additional file 1: Web Appendix 2
bRussia and its surrounding countries (Belarus, Moldova, Russia and Ukraine)
cTotal is more than the sum of the regions because of non-WHO member states
Table 3 Global alcohol-attributable deaths from cardiovascular diseases in 2012 from the 2014 GSRAH [19] and based on the latest
meta-analyses
Disease Men Women Total
Conduction disorder and other dysrhythmias 7,373 7,835 15,208
Hypertension 70,051 24,664 94,714
Haemorrhagic stroke 245,930 132,828 378,757
Ischaemic heart disease 54,499 150,121 204,620
Ischaemic stroke 64,040 23,042 87,082
Total CVD current analysis 441,893 338,490 780,381
From [19]
Ischaemic heart disease 111,755 417,469 529,225
Ischaemic stroke 64,390 45,979 110,369
Total CVD 499,499 628,775 1,128,273
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Discussion
Statement of principal findings
We used the most recent meta-analyses to estimate the
global mortality burden for 2012, and found marked dif-
ferences in the burden for both IHD and IS, with the new
results being 348,000 deaths lower globally (primarily in
women) compared to current WHO GSRAH estimates.
However, the overall impact of alcohol consumption on
CVD is still detrimental, with approximately 780,000 deaths
due to CVD attributable to alcohol consumption globally.
While this article is restricted to CVD outcomes, it should
be stated, however, that the overall detrimental effect of al-
cohol is mainly via cancer, alcohol use disorders, liver cir-
rhosis, and unintentional and intentional injury [19].
Strengths and weaknesses of the study
In our revision, we used the most recent meta-analyses
[21–23] and restricted ourselves to the data range of
these analyses to avoid problems based on just extrapo-
lating trends which is especially problematic for expo-
nential trends. A further strength of this strategy is that
all of the studies to date were included in a systematic
fashion. However, the results of all systematic reviews
and meta-analyses can only be as good as the underlying
data, and in the field of alcohol epidemiology, there is
still a scarcity of well conducted studies which separate
the effects of different patterns of drinking (for listing of
relevant studies see [22, 46]; for the general question see
[49]). Thus, while the proposed methodology is based on
the best available evidence systematically collected, there
are still many holes in the literature on the impact of dif-
ferent drinking pattern on CVD outcomes.
Second, we set the RR (compared to lifetime abstainers)
to at least 1 if people had irregular or regular heavy drink-
ing occasions, which is justified by the underlying recent
meta-analyses. Finally, we used disease-specific RRs for
former drinkers (i.e., sex-specific RRs for IHD and IS from
[36, 37]), and capped the prevalence of former drinkers in
regions where sick quitters are less likely (e.g., in regions
where lifetime abstention is the norm and where many
former drinkers likely drank only for a short period of
time). The capping of the prevalence of former drinkers
was determined to be the most important factor contrib-
uting to the differences between the 2014 GSRAH esti-
mates and the estimates provided in this paper. Clearly,
more research is necessary on former drinkers in low- and
middle income countries, which will hopefully inform fur-
ther iterations of the As a result, it is likely that the esti-
mates presented in this paper are a more accurate
representation of the burden of alcohol consumption than
are the 2014 GSRAH estimates.
The exposure data from the 2014 GSRAH have been
validated by experts in the respective countries (for de-
tailed description of the procedures used: [27]; see also
[50]), and are based on a triangulation of per capita con-
sumption with survey data [51, 52]. While this proced-
ure cannot eliminate all biases, especially in countries
with high unrecorded consumption [53, 54], it does cor-
rect for errors and biases stemming from survey-based
data (for reasoning, see [51, 52]; for estimating uncer-
tainty, see [55]). In other words, the underestimation of
consumption via surveys, where in some countries like
Canada the survey responses covered less than 35 %
of the per capita consumption which is mostly based
on taxation ([56]; general discussion in [51, 52]),
could be avoided. However, as indicated above, unre-
corded consumption may contain considerable meas-
urement bias [53, 54].
Mortality data are mainly based on verbal autopsies, es-
pecially in low-income countries, and while they certainly
contain errors, they are the best available current data
[57]. Lastly, the new RR estimates used in this study were
based on a larger pool of studies, and thus constitute an
improvement. In addition, we were able to base alcohol
burden estimates on disease- and sex-specific meta-
analyses, and to use age-specific relative risk functions.
Strengths and weaknesses in relation to other studies,
discussing important differences in results
As indicated above, this study is the only one to date
which incorporated the latest evidence from systematic
reviews and meta-analyses. Thus, it constitutes the best
effort to date to model the impact of alcohol on CVDs.
All prior efforts [11, 18, 58] used the same principal
methodology, but employed less comprehensive meta-
analyses on risk relations, and fewer systematic searches
for exposure data.
Meaning of the study
The best possible estimate of the impact of alcohol on
CVD mortality revealed an important global detrimental
effect. A relatively large proportion of these deaths stem
from Russia and surrounding countries, with their spe-
cific combination of overall high volume of alcohol con-
sumption coupled with prolonged binges [34, 35, 59–61].
Accordingly, policy makers should act to reduce overall al-
cohol consumption as well as heavy drinking occasions in
order to reduce the alcohol-attributable burden of disease
in general and the alcohol-attributable non-communicable
disease burden in particular [62].
Further unanswered questions and future research
There is an ongoing debate as to whether the beneficial
effects of alcohol consumption in terms of a protective
effect on ischaemic diseases are real. The newest con-
tribution to this discussion comes from Mendelian
randomization studies [63, 64], where Holmes and col-
leagues [63] recently investigated the role of alleles of
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the ADH1B gene on IHD risk. The rs1229984 A-allele
has been found to lead to an increased metabolization of
alcohol into acetaldehyde [65] (acetaldehyde is associ-
ated with negative effects, including a flushing response).
Holmes and colleagues showed that carrying the
rs1229984 A-allele was associated with less consumption
in terms of both average alcohol consumption and binge
drinking, and with a lower IHD risk. While Holmes and
colleagues concluded that there is no beneficial effect of
alcohol consumption on IHD risk, their findings do not
rule out a beneficial effect of low average alcohol con-
sumption without binge drinking. However, the findings
highlight the need for careful interpretation of the
evidence. Meta-analyses of high quality observational
studies, supported by short-term experimental studies
on biomarkers for IHD risk, identified a curvilinear rela-
tionship between average alcohol consumption and IHD
risk, and a modifying effect from episodic heavy drinking
(see also [66]). We would expect on average low or mod-
erate alcohol consumption coupled with no binge drink-
ing to show less IHD risk compared to other drinkers. If
this rather complex relationship is not reflected in the
analysis, interpretation becomes increasingly difficult.
Moreover, certain assumptions must be met in order to
assess the validity of the findings from a Mendelian
randomization analysis, and the conclusions of such an
analysis depend on these assumptions. First, it was as-
sumed that all of the effect of the allele was mediated
through alcohol consumption. However, only a small
percentage of the variation of alcohol consumption is
explained by ADH1B genotypes, or by other genes re-
lated to alcohol consumption, such as ALDH2. Further-
more, it is assumed that the risk for IHD is identical for
carriers and non-carriers, except for the effect of the
allele. Additionally, the effect of the allele, other than
a reduction in alcohol exposure, must be independent
from IHD risk. However, Holmes and colleagues dem-
onstrated that the rs1229984 A-allele was associated
with several IHD risk factors. Another problem lies in
the statistical power required to examine such a com-
plex association. Only a small percentage of the
population studied by Holmes and colleagues carried
the rs1229984 A-allele and, thus, investigations in
populations where carriers are more common might
remedy this problem. While Mendelian randomization
has theoretical advantages over observational studies,
it is unknown whether such an investigation of the
ADH1B gene meets the assumptions necessary to
yield unbiased results, particularly in more complex
analyses. More research on the influence of several
different genes on alcohol consumption and their in-
fluence on IHD risk is necessary to validate and
correctly interpret the findings from this and other
Mendelian randomization studies.
The above discussion illustrates that the relationship
between alcohol and CVDs is still very much under
examination. However, the new data presented in this
article reflect the current state of knowledge and are
based on a more robust evidence base than any prior
estimates. Thus, unless the knowledge base changes
substantially, these new estimates can be considered the
best estimates for modelling the impact of alcohol con-
sumption on CVDs.
Conclusions
When the most comprehensive and recent systematic
reviews and meta-analyses are taken as bases and when
two dimensions of alcohol consumption are included,
the net impact of alcohol consumption on CVD is lower
than previously estimated.
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